The Centers for Disease Control and Prevention (CDC) launched its website yesterday, based on Microsoft's Healthcare Bot service

Adaptive BioTechnologies is a Seattle-based start-up with a broad mission to understand the response of the human immune system to disease and ultimately to develop a

The cooperation with Microsoft will promote the research and commercial work of vaccines. In their collaboration, they will map a large-scale population adaptive immune response to the disease to study the coronavirus. If the characteristics of immune response are found, it may promote the diagnosis, treatment and prevention of the disease solutions, thus increasing the existing research work.

Also, through open data access, Microsoft and Adaptive are free to researchers, public health officials or organizations around the world.

From next month, Adaptive BioTechnologies said, it will launch a virtual clinical study by collecting blood samples of new coronavirus infections or rehabilitated people. DNA sequencers from Illumina will be used to sort immune cell receptors. all data collected around the immune response will be uploaded to the open data access portal for use by researchers.

Microsoft will provide its cloud computing and machine learning technologies to help understand these samples. Peter, Microsoft Research Directo